SCHEMBL6933682

SCHEMBL6933682

O=c1[nH]c(SCCOc2ccccc2)nc(-c2ccncc2)c1-c1ccc(F)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 10/20 0.55
MAPK13 O15264 3/20 0.55
MAPK12 P53778 3/20 0.55
MAPK11 Q15759 3/20 0.55
MAOB P27338 1/20 0.53
KDM4E B2RXH2 2/20 0.47
GAA P10253 1/20 0.47
NPSR1 Q6W5P4 2/20 0.46
TSHR P16473 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
NPC1 O15118 1/20 0.45
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45
AR P10275 1/20 0.45
THRB P10828 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6934568 0.85 MAPK14 (0.62) MAPK14MAPK13MAPK12MAPK11
SCHEMBL6934204 0.83 MAPK14 (0.59) MAPK14MAPK13MAPK12MAPK11MAOB
SCHEMBL7215128 0.83 MAPK14 (0.56) MAPK14MAPK13MAPK12MAPK11
SCHEMBL7216599 0.78 MAPK14 (0.47) MAPK14MAPK13MAPK12MAPK11KDM4E
SCHEMBL6934771 0.76 MAPK14 (0.67) MAPK14MAPK13MAPK12MAPK11
SCHEMBL6932744 0.73 MAPK14 (0.67) MAPK14MAPK13MAPK12MAPK11KDM4E
SCHEMBL6933891 0.70 MAPK14 (0.64) MAPK14MAPK13MAPK12MAPK11KDM4E
SCHEMBL6934304 0.70 MAPK14 (0.55) MAPK14MAPK13MAPK12MAPK11NPSR1
SCHEMBL4464755 0.70 MAPK14 (0.80) MAPK14MAPK13MAPK12MAPK11
SCHEMBL6932122 0.70 MAPK14 (0.61) MAPK14MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6649604-B2 Analgesics; antidiabetic agents; antiinflamamtory agents AMGEN INC. 2003-11-18 US disclosed
US-6610698-B2 Treatment of tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and interleukin-8 mediated diseases AMGEN, INC. 2003-08-26 US disclosed
US-20030073704-A1 Substituted pyridone compounds and methods of use AMGEN INC. 2003-04-17 US disclosed
US-20030069425-A1 Substituted pyrimidine compounds and methods of use AMGEN INC. 2003-04-10 US disclosed
US-6420385-B1 INFLAMMATORY, PAIN AND DIABETES DISEASES, AMGEN INC. 2002-07-16 US disclosed
US-6410729-B1 ANALGESICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATORY AGENTS AMGEN INC. 2002-06-25 US disclosed
US-6096753-A Substituted pyrimidinone and pyridone compounds and methods of use AMGEN INC. (US) 2000-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069425-A1 Substituted pyrimidine compounds and methods of use DPYD, IL6, IL1B MAPK14 2062/4885MAPK13 2250/4885MAPK12 1502/4885
US-20030073704-A1 Substituted pyridone compounds and methods of use IL6, IL1B, IL1A MAPK14 1169/4885MAPK13 1577/4885MAPK12 1127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.